Abstract
Sooner or later—depending on whether and how well and quickly biomedical research reforms—all genes and their importance in maintaining health and curing disease will be elucidated. However, you, dear reader, will personally only be able to benefit from this if you also know your own genes and variants. But what exactly does that look like and how does that work, “knowing your genes?”
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Wojcik GL et al. (2019) Genetic analyses of diverse populations improves discovery for complex traits. Nature 570:514–518, https://doi.org/10.1038/s41586-019-1310-4
- 2.
White JD et al. (2021) Insights into the genetic architecture of the human face. Nat Genet 53:45–53, https://doi.org/10.1038/s41588-020-00741-7
- 3.
International Society of Genetic Genealogy (2016) Regulation of genetic tests, https://isogg.org/wiki/Regulation_of_genetic_tests
- 4.
- 5.
AACC (2021) FDA OKs 23andMe to Report Pharmacogenomic Variants Without Confirmatory Testing, https://www.aacc.org/cln/articles/2021/july/fda-oks-23andme-to-report-pharmacogenomic-variants-without-confirmatory-testing
- 6.
- 7.
Venter JC et al. (2001) The Sequence of the Human Genome, Science 291:1304–1351, https://doi.org/10.1126/science.1058040; Lander ES et al. (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921, https://doi.org/10.1038/35057062
- 8.
- 9.
Slamon DJ et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244:707–712; Slamon DJ et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182; Baselga J et al. (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer, Semin Oncol 26:78–83; Shak S et al. (1999) Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group, Semin Oncol 26:71–77; Editor (1998) Pharmacogenomics at work. Nat Biotechnol 16:885; Mass R (2000) The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 27:46–52; Haseltine WA (2000) Not quite pharmacogenomics. Nat Biotechnol 16:1295
- 10.
Klein EA et al. (2021) Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology 32:1167–1177, https://doi.org/10.1016/j.annonc.2021.05.806
- 11.
Chen R et al. (2012) Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. Cell 148:1293–1307, https://doi.org/10.1016/j.cell.2012.02.009
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Schmidt, H.H.H.W. (2022). Know your Genes. In: The end of medicine as we know it - and why your health has a future. Springer, Cham. https://doi.org/10.1007/978-3-030-95293-8_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-95293-8_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-95292-1
Online ISBN: 978-3-030-95293-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)